Competitive Generic Therapies: Off-Patent Drugs With 1-4 Sources
✉ Email this page to a colleague
This table lists drugs which, despite having no patents or regulatory protections, have a limited number of active sources.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Strength |
|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Ltd | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 090159-001 | Nov 15, 2018 | AB | RX | No | No | EQ 600MG BASE;300MG |
| Chartwell Rx | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 204990-001 | Mar 28, 2017 | AB | RX | No | No | EQ 600MG BASE;300MG |
| Cipla | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 091144-001 | Mar 28, 2017 | AB | RX | No | Yes | EQ 600MG BASE;300MG |
| Laurus | ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 216332-001 | Jul 25, 2022 | AB | RX | No | No | EQ 600MG BASE;300MG |
| Lupin Ltd | ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 202912-001 | Dec 5, 2013 | RX | No | Yes | EQ 300MG BASE;150MG;300MG | |
| Mylan | ACAMPROSATE CALCIUM | acamprosate calcium | TABLET, DELAYED RELEASE;ORAL | 200142-001 | Mar 11, 2014 | AB | RX | No | No | 333MG |
| Zydus Pharms | ACAMPROSATE CALCIUM | acamprosate calcium | TABLET, DELAYED RELEASE;ORAL | 205995-001 | May 26, 2017 | AB | RX | No | Yes | 333MG |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Strength |
